Antiatherogenic Effects of Angiotensin II Receptor Blocker Olmesartan: Mechanisms, Intensity and Clinical Significance

S.M. Koval, L.A. Ryeznik, I.O. Snigurska, O.V. Mysnychenko

Abstract


This review presents the evidence in the literature that suggest a key pathogenetic role of the renin-angiotensin system and its main neurohormone angiotensin II in the development of atherosclerosis and the powerful antiatherogenic properties of an angiotensin II receptor blocker olmesartan. It is shown that the antiatherogenic effect of olmesartan is presented through a strong antioxidant and antiinflammatory effects and its normalizing effect on endothelial function. A detailed analysis of the literature indicates that strong evidence of significant antiatherogenic action of olmesartan is obtained in the experimental, clinical, and prospective multicenter randomized trials (EUTOPIA, MORE, VIOS, OLIVUS, OLIVUS-Ex). These data substantiate the prospect of wide application of olmesartan in the treatment of hypertension, especially in combination with atherosclerosis.


Keywords


angiotensin II receptor blockers; olmesartan; antiatherogenic effects

References


Березин А.Е. Клиническая эффективность и безопас­ность применения олмесартана — нового антагониста рецепторов к ангиотензину II — у пациентов с артериальной гипертензией // Український медичний часопис. — 2009. — № 3(71). — С. 1-6.

Міщенко Л.А., Свіщенко Є.П., Яринкіна О.А. Предиктори прогресування ураження сонних артерій у хворих на гіпертонічну хворобу // Серце і судини. — 2013. — № 1. — С. 47-53.

Настанова з артеріальної гіпертензії / За ред. В.М. Коваленка, Є.П. Свіщенко, Ю.М. Сіренка. — К.: Моріон, 2010. — 492 с.

Серцево-судинні захворювання. Рекомендації з діагностики, профілактики та лікування / За ред. В.М. Коваленка, М.І. Лутая. — К.: Моріон, 2011. — 408 с.

Cиренко Ю.Н., Рековец О.Л. Роль олмесартана в лечении артериальной гипертензии // Артериальная гипертензия. — 2009. — № 2(4). — С. 48-58.

Agabiti Rosei E., Muiesan M.L. Essessment of preclinical target organ damage in hypertension: carotid intima-media thickness and plaque // European Society of Hypertension. Clinical Practice Newsletters. — Update 2011. — Р. 19-20.

Agata J., Ura N., Yoshida H. et al. Olmesartan is angiotensin II receptor blocker with an ingibitory effect on angiotensin-conver­ting enzyme // Hypertens. Res. — 2006. — 29. — Р. 865-874.

Akinboboye O.O., Chou R.L., Bergmann S.R. Augmentation of myocardial blood flow in hypertensive heart disease by angiotensin antagonists: a comparison of lisinopril and losartan // J. Am. Coll. Cardiol. —2002. — 40. — Р. 703-709.

Brunner H.R., Stumpe K.O., Junuszewicz A. Antihypertensive efficacy of olmesartan medoxomil and candesartan cilexitil assessed by 24-hour ambulatory blood preasure monitoring in patients with essential hypertension // Clin. Drug. Invest. — 2003. — V. 23. — Р. 419-430.

Cicha I., Urschel K., Daniel W.G. Olmesartan and amplodi­pine inhibit non-uniform shear stress-induced activation of endothelial cells and prevent monocytic cell chemotaxis and adhesion to endothelium // European Heart J. — 2011. — Vol. 32 (Abstract Supplement). — Р. 514.

Csajka C., Buclin T., Brunner H.R., Biollaz J. Pharmacokinetic — pharmacodynamic profile of angiotensin II receptor antagonists // Clin. Pharmacokinet. — 1997. — 32. — Р. 1–29.

Da Cunha V., Martin-McNulty B., Vincelette J. et al. Angiotensin II induces histomorphologic features of unstable plaque in a murine model of accelerated atherosclerosis // J. Vasc. Surg. — 2006. — 44(2). — Р. 364-371.

Deanfield J., Donald A., Ferri C. et al. Endothelial function and dysfunction. Part 1: methodological issues for assessment in the different vascular beds: a statement by the Working Group on Endothelin and Endothelial Factors of the Europian Society of Hypertension // J. Hypertens. — 2005. — 23(1). — Р. 7-17.

Doi T., Sakoda T., Akagami T. et al. T-type Ca2+ channel antagonists attenuated aldosterone induces endothelin-1-Rho/Rho-kinase-interleukin-18 pathway in cardiomyocytes // European Heart J. — 2012. — Vol. 32 (Abstract Supplement). — Р. 1045.

Ferrario C.M., Strawn W.B. Role of the renin-angiotensin-aldosterone system and proinflammatory mediators in cardiovascular disease // Am. J. Cardiol. — 2006. — 98(1). — 121-128.

Fliser D., Buchholz K., Haller H. Antiinflammatory effects of angiotensin II subtype 1 receptor blockade in hypertensive patients with microinflammation // Circulation. — 2004. — 110(9). — 1103-1107.

Hilgers K.F., Stumpf C. Angiotensin II, the endothelium and superoxide anions // J. Hypertension. — 2002. — Vol. 20. — P. 1271-1273.

Hirohata A., Yamamoto K., Miyoshi T. et al. Impact of olme­sartan on progression of coronary atherosclerosis: a serial volumetric intravascular ultrasound analysis from the OLIVUS (impact of olme­sarten on progression of coronary atherosclerosis: evaluation by intravascular ultrasound) trial // J. Am. Coll. Cardiol. — 2010. — 55(10). — 976-982.

Hirohata A., Yamamoto K., Miyoshi T. et al. Four-year clinical outcomes of the OLIVUS-Ex (impact of Olmesartan on progression of coronary atherosclerosis: evaluation by intravascular ultrasound) extension trial // Atherosclerosis. — 2012 Jan. — 220(1). — 134-8.

Kyotani Y., Zhao J., Tomita S. et al. Olmesartan inhibits angiotensin II-induced migration of vascular smooth muscle cells through Src and mitogen-activated protein kinase pathways // J. Pharmacol. Sci. — 2010. — 113(2). — 161-168.

Li J.J., Chen J.L. Inflammtion may be a bridge connecting hypertension and atherosclerosis // Med. Hypotheses. — 2005. — 64(5). — Р. 925-929.

Lonn E., Yusuf S., Dzavik V., Doris C., Yi Q., Smith S., Moore-Cox A., Bosch J., Riley W., Teo K. Effects of ramipril and vitamin E on atherosclerosis: the study to evaluate carotid ultrasound changes in patients treated with ramipril and vitamin E (SECURE) — SECURE Investigators // Circulation. — 2001 Feb 20. — 103(7). — 919-25.

Malacco Е., Omboni S., Volpe M. et al. Antihypertensive efficacy and safety of olmesartan medoxomil and ramipril in elderly patients with mild to moderate essential hypertension: the ESPORT study // Journal of Hypertension. — 2010. — V. 28(11). — Р. 2342-2350.

Mancia G., De Backer G., Dominiczak A. et al. 2007 Guidelines for the Management of Arterial Hypertension. The task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and for the European Society of Cardiology (ESC) // J. Hypertens. — 2007. — 25. — Р. 1105-1187.

Mason R.P. Nitric oxide mechanisms in the pathogenesis of global risk // J. Clin. Hypertens. (Greenwich). — 2006. — 8 ­(Suppl. 2). — Р. 31-38.

Mason R.P. Оптимальная терапевтическая стратегия для лечения пациентов с артериальной гипертензией и атеросклерозом: в центре внимания олмесартана медоксомил // Therapia (Український медичний вісник). — 2011. — № 7–8(60). — С. 3-13.

Matsumoto K., Morishita R., Tomita N. et al. Improvement of endothelial dysfunction by angiotensin II blockade accompanied by induction of vascular hepatocyte growth factor system in diabetic spontaneously hypertensive rats // Heart Vessels. — 2003. — 18(1). — 18-25.

Mazzolai L., Duchosal M.A., Korber M. et al. Endogenous angiotensin II induces atherosclerotic plaque vulnerability and eli­cits a Th1 response in apoE–/– mice // Hypertension. — 2004. — Vol. 44. — P. 277-283.

Mizuno M., Sada T. Pharmocology of CS-866, a novel nonpeptide angiotensin antagonist II reseptor antagonist // Eur. J. Pharmacol. — 1999. — 285. — 181-188.

Mizuno Y., Jacob R.F., Mason R.P. Advance in farmacologic modulation of nitric oxide in hypertension // Car. Cardiol. Rep. — 2010. — 12(60). — Р. 472-480.

Nakayama S., Watada H., Mita T. et al. Comparison of Effects of Olmesartan and Telmisartan on Blood Pressure and Metabolic Parameters in Japanese Early-Stage Type-2 Diabetics with Hypertension // Hypertens. Res. — 2008. — 31(1). — Р. 7-13.

Napoli C., Bruzzese G., Ignarro L.J., Crimi E., de Nigris F., Williams-Ignarro S., Libardi S., Sommese L., Fiorito C., Mancini F.P., Cacciatore F., Liguori A. Long-term treatment with sulfhydryl angiotensin-converting enzyme inhibition reduces carotid intima-media thickening and improves the nitric oxide/oxidative stress pathways in newly diagnosed patients with mild to moderate primary hypertension // Am. Heart J. — 2008 Dec. — 156(6). — 1154-1178.

Naya M., Tsukamoto T., Morita K. et al. Olmesartan, but not amlodipine, improves endothelium-dependent coronary dilation in hypertensive patients // J. Am. Coll. Cardiol. — 2007 Sep 18. — 50(12). — Р. 1144-1149. Epub 2007 Sep 4.

Ono H., Minatoguchi S., Watanabe K., Yamada Y., Mizukusa T., Kawasaki H., Takahashi H., Uno T., Tsukamoto T., Hiei K., Fujiwara H. Candesartan decreases carotid intima-media thickness by enhancing nitric oxide and decreasing oxidative stress in patients with hypertension // Hypertens. Res. — 2008 Feb. — 31(2). — Р. 271-9.

Rosei E.A., Rissoni D., Muiesan M.L. et al. Effects of candesartan cilexetil and enalapril on inflammatory markers of athe­rosclerosis in hypertensive patients with non-insulin-dependent diabetes mellitus // J. Hypertens. — 2005. — 23(2). — Р. 435-444.

Ross R. Atherosclerosis-an inflammatory disease // N. Ingl. J. Med. — 1999. — 340(2). — Р. 115-126.

Ruiz-Ortega M., Ruperez M., Esteban V. et al. Angiotensin II: a key factor in the inflammatory and fibrotic response in kidney diseases // Nephrol. Dial. Transplant. — 2006. — 21(1). — Р. 16-20.

Sakamoto N., Ishibashi T., Sugimoto K. et al. LOX-1 cooperates with renin-angiotensin system in monocyte adhesion-induced redox-sensitive and Ca2+ signaling pathways in endothelial cells // European Heart J. — 2010. — Vol. 31 (Abstract Supplement). — Р. 95.

Savoi C., Rossi C., Arrabito E. MAS receptor activation contributes to the improvement of vascular remodelling induced by the angiotensin receptor blocker olmesartan in spontaneously hypertensive rats // European Heart J. — 2010. — Vol. 31 (Abstract Supplement). — Р. 700.

Schmieder R.E., Hilgers K.F., Schlaich M.P., Schmidt B.M. Renin-angiotensin system and cardiovascular risk // Lancet. — 2007. — 369(9568). — Р. 1208-1219.

Shimada K., Murayama T., Yokode M., Kita T., Fujita M., Kishimoto C. Olmesartan, a novel angiotensin II type 1 receptor antagonist, reduces severity of atherosclerosis in apolipoprotein E deficient mice associated with reducing superoxide production // Nutr. Metab. Cardiovasc. Dis. — April 14 2010.

Singh U., Jialal I. Oxidative stress and atherosclerosis // Pathophysiology. — 2006. — 13(3). — Р. 129-142.

Smith D.H. Dose-response characteristics of olmesartan medoxomil and other angiotensin II reseptor blocker // Am. J. Cardiovasc. Drugs. — 2007. — V. 7. — Р. 347-356.

Smith D.H. Comparison of angiotensin II reseptor blocker in the treatment of essential hypertension // Drugs. — 2008. —

V. 68. — Р. 1207-1245.

Smith R.D., Yokoyama H., Averill D.B., Schiffrin E.L., Ferrario C.M. Reversal of vascular hypertrophy in hypertensive patients through blockade of angiotensin II receptors // J. Am. Soc. Hypertens. — 2008. — 2(3). — 165-172.

Sonoda M., Aoyagi T., Takenaka K. et al. A One-Year Study of the Antiatherosclerotic Effect of the Angiotensin-II Receptor Blocker Losartan in Hypertensive Patients (A Comparison With Angiotensin-Converting Enzyme Inhibitors) // Int. Heart. J. — 2008. — Vol. 49, № 1. — P. 95-103.

Stumpe K.O., Agabiti-Rosei E., Zielinski T., Schremmer D., Scholze J., Laeis P., Schwandt P., Ludwig M. Carotid intima-media thickness and plaque volume changes following 2-year angiotensin II-receptor blockade. The Multicentre Olmesartan atherosclerosis Regression Evaluation (MORE) study // Ther. Adv. Cardiovasc. Dis. — 2007 Dec. — 1(2). — 97-106.

Takai S., Jin D., Sakaguchi M., Muramatsu M., Miyazaki M. The regressive effect of an angiotensin II receptor blocker on formed fatty streaks in monkeys fed a high-cholesterol diet // J. Hypertens. — 2005. — 23(10). — 1879-1886.

Touyz R.M., Schiffrin E.L. Reactive oxygen species in vascular biology: implication in hypertension // Hystochem. Cell Biol. — 2004. — 122(4). — Р. 339-352.

Triantafyllii H., Trivilou P., Ikonomidis I. et al. Irbesartan and subclinical target organ damage after three years of treating never treated patients with essential hypertension // European Heart J. — 2010. — Vol. 31 (Abstract Supplement). — Р. 691.

Weiss D., Sorescu D., Taylor W.R. Angiotensin II and atherosclerosis // Am. J. Cardiol. — 2001. — 87(8 A). — 25C-32C.




DOI: https://doi.org/10.22141/2224-1485.2.28.2013.86518

Refbacks

  • There are currently no refbacks.


Copyright (c) 2016 HYPERTENSION

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

 

© Publishing House Zaslavsky, 1997-2017

 

 Яндекс.МетрикаSeo анализ сайта Рейтинг@Mail.ru